Table 1.

Characteristics of included cohorts.

Year	First Author	Cohort	Sample Size	Population	Countries	Outcomes	Follow-up Period
2010	Brickman10	WHICAP	686	Older adults 65+ years of age	USA	Stroke	4.5 ± 0.8 years (mean)
2008	Brunelli11	ArMORR	6,961	Adult hemodialysis patients	USA	All-cause mortality, CVD mortality	185 days (median); range 181–365 days
2012	Carr12	MRC Elderly Trial	4,396	Elderly hypertensive patients	UK	CHD, stroke	5.8 years (mean)
2014	Chang13	HEMO	1,844	Adult hemodialysis patients	USA	All-cause mortality, CVD mortality	2.5 years (median); IQR 1.3–4.3 years
2014	Chowdhury14	ANPB2	In-trial: 5,880 Post-trial: 5,542	Elderly hypertensive patients	Australia	In-trial: CVD (fatal and non-fatal), MI (fatal and non-fatal), stroke (fatal and non-fatal) Post-trial: Fatal CVD, fatal MI, fatal stroke	In-trial: 4.1 years (median) Post-trial: 6.9 years post-trial (median)
2012	Di Iorio16	N/A	374	Adult CKD patients	Italy	All-cause mortality	33 ± 21 months (mean)
2013	Di Iorio15	N/A	1,088	Adult hemodialysis patients	Italy	All-cause mortality, CVD mortality	5 years (max)
2012	Eguchi17	Karatsu- Nishiarita Study	457	Adult hypertensive patients	Japan	Hard CVD (stroke, MI, sudden cardiac death)	66 ± 27 months (mean)
2014	Gao7	N/A	2,906	Elderly primary care patients	USA	All-cause mortality, CHD mortality, stroke mortality, stroke or CHD mortality	12.9 years (median); range 2–16 years
1997	Grove18	Honolulu Heart	1,433	Middle-age men of Japanese ancestry living in Oahu, HI	USA	CHD	11.6 years (mean)
2013	Hastie1	N/A	14,522	Adult hypertensive patients	Scotland	All-cause mortality, CVD mortality, ischemic heart disease mortality, stroke mortality	35 years (max)
2013	Hata, J.19	ADVANCE Trial	8,811	Adult type 2 diabetic patients	20 countries from Asia, Australasia, Europe, and North America	All-cause mortality, CVD mortality, MI, stroke, major macrovascular events (composite of stroke, MI, CVD mortality)	2.4 years (median)
2000	Hata, Y.20	N/A	521	Elderly hypertensive patients	Japan	Stroke	1 year
2002	Hata, Y.21	N/A	419	Elderly hypertensive patients	Japan	MI	1 year
1983	Hofman22	Framingham	3,350	Adult general population	USA	All-cause mortality, CHD, CVD	26 years (max)
2012	Hsieh23	N/A	2,161	Adult type 2 diabetic patients	Taiwan	All-cause mortality, CVD mortality	66.7 ± 7.5 months (mean); range 21–80 months
2013	Kawai24	NOAH	485	Adult hypertensive patients	Japan	CVD	7.6 ± 2.6 years (mean)
2013	Kim25	N/A	2,174	Adult hemodialysis patients	Korea	All-cause Mortality	46.5 months (mean)
2013	Kostis26	SHEP	4,736	Elderly with isolated systolic hypertension	USA	CVD Mortality	Range 11.7 – 15.0 years
2013	Lau27	N/A	281	Patients with recent lacunar infarct	Hong Kong	ACS, all-cause mortality, CVD mortality, stroke	78 ± 18 months (mean)
2014	Lau28	N/A	632	Patients with recent ischemic stroke	Hong Kong	ACS, all-cause mortality, CVD mortality, stroke	76 ± 18 months
2013	Mallamaci29	N/A	1,618	Adult CKD patients	Italy	Composite of all-cause mortality and fatal and non-fatal CVD	37 months (median); range 0.3–110 months
2012	Mancia6	ELSA	1,521	Adult hypertensive patients	Europe (France, Germany, Greece, Italy, Spain, Sweden, UK	CVD	4 years (max)
2013	McMullan30	AASK	908	Adult African Americans with CKD	USA	All-cause mortality, CVD, CVD mortality	52 months (median); 75 months (max)
2011	Muntner2	NHANES III	956	Adult general population	USA	All-cause mortality	14 years (median)
2012	Poortvliet (Short Term)31	PROSPER	4,819	Elderly adults with or at risk for CVD	Ireland, Scotland, The Netherlands	All-cause mortality, coronary events, stroke (fatal and non-fatal), vascular mortality	3 years (max); 2.3 years (mean)
2012	Poortvliet (Long Term)31	PROSPER	1,808	Elderly adults with or at risk for CVD	Scotland	All-cause mortality, coronary events, stroke (fatal and non-fatal), vascular mortality	7.1 years (mean); 9.3 years (max)
2003	Pringle32	Syst-Eur	744	Elderly hypertensive patients	Europe (23 countries)	CVD, CVD mortality, stroke	4.4 years (median); range 1–109 months
2012	Rossignol33	FOSIDIAL	388	Hemodialysis patients with LVH	France	CVD	2 years (max)
2010	Rothwell3	UK-TIA Aspirin Trial	2,006	Patients with recent TIA or stroke	UK	Stroke	10 follow-up visits, occurring every 4 months (median); range 1–20 visits
2010	Rothwell3	ASCOT- BPLA Trial	18,530	Adult hypertensive patients	Europe (7 countries)	Coronary events, stroke, composite of coronary events and stroke	10 follow-up visits, occurring every 6 months (median)
2010	Rothwell3	ESPS-1 Study	1,247	Patients with recent TIA or stroke (Placebo group)	Europe (6 countries)	Stroke	NR
2010	Rothwell3	Dutch-TIA Trial	3,150	Patients with recent TIA or stroke	The Netherlands	Stroke	NR
2014	Selvarajah34	N/A	203	Adult hemodialysis patients	England	All-cause mortality	2.0 ± 1.3 years (mean)
2014	Shafi35	DEcIDE- ESRD	11,291	Adult hemodialysis patients	USA	All-cause mortality, CVD, CVD mortality	22 months (median); 25th–75th percentile 13–36 months
2012	Shimbo36	WHI	58,228	Post-menopausal women	USA	Stroke	5.4 years (median)
2013	Suchy-Dicey37	CHS	3,852	Elderly general population	USA	All-cause mortality, stroke, MI	9.9 years (mean)
1999	Tozawa38	OKIDS	144	Adult hemodialysis patients	Japan	All-cause mortality, CVD mortality	35.2 ± 8.1 months (mean)
2013	Yinon39	HEALS	11,153	Adult general population	Bangladesh	CVD mortality (all and major), CHD mortality, stroke mortality, all- cause mortality	6.5 years (mean)
2007	Zoppini41	Verona Diabetes Study	1,128	Adult type 2 diabetic patients	Italy	All-cause mortality, cerebrovascular disease mortality, CVD mortality, ischemic heart disease mortality	10 years (max)
2008	Zoppini40	Verona Diabetes Study	1,319	Adult type 2 diabetic patients	Italy	All-cause mortality	10 years (max)

ACS, acute coronary syndrome; CHD, coronary heart disease; CKD, chronic kidney disease; CVD, cardiovascular disease; IQR, interquartile range; LVH, left ventricular hypertrophy; MI, myocardial infarction; N/A, not available; NR, not reported; TIA, transient ischemic attack.

Data in table are sorted in alphabetical order.